
|Videos|December 9, 2021
Recent Data Surrounding the Appropriate Candidates for Long-Acting Cabotegravir for HIV Prevention
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Advertisement
Pharmacy Times spoke with Dr. Elizabeth Sherman, PharmD, about her session at the ASHP Midyear 2021 conference, titled "Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection”.
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
2
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
3
Afamitresgene autoleucel: The First T-Cell Receptor Therapy on the Market
4
FDA Approves Depemokimab as Add-On Maintenance Treatment in Severe Asthma
5












































































































































































































